AbbVie sharpens immunology focus with $10.9 billion Apogee deal

AbbVie has agreed to acquire Apogee Therapeutics in a deal valued at $10.9 billion, marking one of the largest biotech acquisitions of 2026. The move targets Apogee’s pipeline of long-acting immunology and inflammatory disease candidates, aligning with AbbVie’s strategic push into high-growth areas beyond its core HIV and rheumatoid arthritis treatments. The transaction is expected to bolster AbbVie’s position in autoimmune and inflammatory therapies, where competition remains fierce.

Coverage emphasizes the deal’s scale and AbbVie’s aggressive expansion into immunology, with outlets like *Reuters*, *Financial Times*, and *Endpoints News* highlighting its potential to accelerate AbbVie’s pipeline. Local media, including *NBC Boston*, underscored the acquisition’s impact on Waltham, Massachusetts, where Apogee is headquartered. Analysts cited in reports suggest the deal could spur further consolidation in the biotech sector, with *Yahoo Finance* noting other potential takeover targets in the space.

Next steps include regulatory approvals and integration planning, though no timeline has been specified. AbbVie’s stock and Apogee’s valuation may face scrutiny as the deal progresses, with investors monitoring whether the price reflects the candidates’ commercial potential. The broader biotech market could see increased M&A activity as competitors assess AbbVie’s strategy.